Abraxis BioScience, Inc.
Abraxis BioScience Reports 2009 Fourth Quarter and Full Year Financial Results
Published in Medical Letter on the CDC and FDA, March 28th, 2010
As of January 2, 2009, the company re-acquired the exclusive rights to market ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the U.S. As a result, beginning in 2009, the company no longer recognizes deferred revenue related to the previous co-promotion agreement. Fourth Quarter 2009 Highlights Net revenue for the fourth quarter of 2009 was $104.7 million compared with $92.2 million for the fourth quarter of 2008. ABRAXANE...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Cooney Waters Group, Inc.
Study reinforces role of AED Vimpat lacosamide C-V as add-on treatment for POS - Infectious Diseases Society of America
Aggressive response helped Chilean hospital improve H1N1 influenza outcomes - Tufts University, Health Sciences
Novel antitoxin strategy developed using 'tagged binding agents' - Biopharmaceuticals
Data on biopharmaceuticals detailed by researchers at University of Helsinki - Cancer
Reports on cancer findings from University of Athens provide new insights - Chemstar Corporation
Chemstar Corporation Recognizes the New FDA Food Code - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
